Login to Your Account



Actelion Jumps as PAH Drug Macitentan Aces Pivotal Trial

By Cormac Sheridan
Staff Writer

Wednesday, May 2, 2012
Shares in Actelion Ltd. rose 13 percent Monday on news that macitentan, its dual endothelin receptor antagonist (ERA), hit the primary endpoint in a pivotal Phase III trial in pulmonary arterial hypertension (PAH), raising the prospect that the company will be able to revitalize its aging PAH franchise with a safer, more potent drug.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription